Literature DB >> 14627696

Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3.

Ute Krengel1, Lise-Lotte Olsson, Carlos Martínez, Ariel Talavera, Gertrudis Rojas, Elin Mier, Jonas Angström, Ernesto Moreno.   

Abstract

N-glycolyl GM3 ganglioside is an attractive target antigen for cancer immunotherapy, because this epitope is a molecular marker of certain tumor cells and not expressed in normal human tissues. The murine monoclonal antibody 14F7 specifically recognizes N-glycolyl GM3 and shows no cross-reactivity with the abundant N-acetyl GM3 ganglioside, a close structural homologue of N-glycolyl GM3. Here, we report the crystal structure of the 14F7 Fab fragment at 2.5 A resolution and its molecular model with the saccharide moiety of N-glycolyl GM3, NeuGcalpha3Galbeta4Glcbeta. Fab 14F7 contains a very long CDR H3 loop, which divides the antigen-binding site of this antibody into two subsites. In the docking model, the saccharide ligand is bound to one of these subsites, formed solely by heavy chain residues. The discriminative feature of N-glycolyl GM3 versus N-acetyl GM3, its hydroxymethyl group, is positioned in a hydrophilic cavity, forming hydrogen bonds with the carboxyl group of Asp H52, the indole NH of Trp H33 and the hydroxyl group of Tyr H50. For the hydrophobic methyl group of N-acetyl GM3, this environment would not be favorable, explaining why the antibody specifically recognizes N-glycolyl GM3, but not N-acetyl GM3. Mutation of Asp H52 to hydrophobic residues of similar size completely abolished binding. Our model of the antibodycarbohydrate complex is consistent with binding data for several tested glycolipids as well as for a variety of 14F7 mutants with replaced VL domains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627696     DOI: 10.1074/jbc.M311693200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody.

Authors:  Caroline Soliman; Jia Xin Chua; Mireille Vankemmelbeke; Richard S McIntosh; Andrew J Guy; Ian Spendlove; Lindy G Durrant; Paul A Ramsland
Journal:  J Biol Chem       Date:  2019-12-12       Impact factor: 5.157

3.  Antibody recognition of cancer-related gangliosides and their mimics investigated using in silico site mapping.

Authors:  Mark Agostino; Elizabeth Yuriev; Paul A Ramsland
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

4.  Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture.

Authors:  Kaare Bjerregaard-Andersen; Hedda Johannesen; Noha Abdel-Rahman; Julie Elisabeth Heggelund; Helene Mykland Hoås; Fana Abraha; Paula A Bousquet; Lene Støkken Høydahl; Daniel Burschowsky; Gertrudis Rojas; Stefan Oscarson; Geir Åge Løset; Ute Krengel
Journal:  Sci Rep       Date:  2018-07-18       Impact factor: 4.379

5.  Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.

Authors:  Denise Dorvignit; Kayluz F Boligan; Ernesto Relova-Hernández; Marilyn Clavell; Armando López; Mayrel Labrada; Hans-Uwe Simon; Alejandro López-Requena; Circe Mesa; Stephan von Gunten
Journal:  Sci Rep       Date:  2019-07-09       Impact factor: 4.379

Review 6.  The Structural Complexity and Animal Tissue Distribution of N-Glycolylneuraminic Acid (Neu5Gc)-Terminated Glycans. Implications for Their Immunogenicity in Clinical Xenografting.

Authors:  Michael E Breimer; Jan Holgersson
Journal:  Front Mol Biosci       Date:  2019-07-19

7.  Key role of a structural water molecule for the specificity of 14F7-An antitumor antibody targeting the NeuGc GM3 ganglioside.

Authors:  Kaare Bjerregaard-Andersen; Fana Abraha; Hedda Johannesen; Stefan Oscarson; Ernesto Moreno; Ute Krengel
Journal:  Glycobiology       Date:  2021-12-18       Impact factor: 4.313

8.  Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines.

Authors:  Mariano R Gabri; Laura L Otero; Daniel E Gomez; Daniel F Alonso
Journal:  J Exp Clin Cancer Res       Date:  2009-12-01

Review 9.  Molecular recognition of gangliosides and their potential for cancer immunotherapies.

Authors:  Ute Krengel; Paula A Bousquet
Journal:  Front Immunol       Date:  2014-07-21       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.